MedTrace Logo

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

NCT02074995 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-03-07

Study results available
· View outcomes & findings →

Summary

Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks

Conditions

  • Hypercatabolic Status Related to Severe Burn

Interventions

BIOLOGICAL

BVS857

Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

OTHER

placebo

Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02074995 on ClinicalTrials.gov